The Mammalian Cells Monoclonal anti-MUC16 (Sofituzumab Biosimilar) antibody (ABIN7488033) specifically detects MUC16 (Sofituzumab Biosimilar) in ELISA.
The antibody is reactive with Human samples.
Research Grade
Reactivity: Human
Host: Humanized
Chimeric
unconjugated
Recombinant Antibody
Restrictions
For Research Use only
Buffer
PBS pH 7.5
Storage
-80 °C
Storage Comment
store at -80°C
Target
MUC16 (Sofituzumab Biosimilar)
Target Type
Biosimilar
Background
DMUC5754A (conjugate),MMUC1206A (nonconjugate) Sofituzumab is investigated for the treatment of Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. Sofituzumab Vedotin (also known as DMUC5754A and RG-7458) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody (mAb) and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl. DMUC5754A binds to the MUC16 extracellular domain with high affinity, and shows potent and selective anti-tumor activity in MUC16-expressing human ovarian cancer (OC) and pancreatic cancer (PC) mouse xenograft models. The targeted therapeutic strategy of DMUC5754A resulted in enhanced tumor-specific activity of MMAE, while minimizing exposure to tissues that do not express MUC16.